• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients.

作者信息

Lemonakis Konstantinos, Tatting Love, Lisak Mikael, Carlson Kristina, Crafoord Jacob, Blimark Cecilie H, Santamaria Antonio I, Wichert Stina, Lenhoff Stig, Hansson Markus

机构信息

Department of Hematology, Skane University hospital, Lund.

Department of Hematology, University hospital Linkoping.

出版信息

Haematologica. 2023 Feb 1;108(2):610-614. doi: 10.3324/haematol.2022.281610.

DOI:10.3324/haematol.2022.281610
PMID:36200424
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9890000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b45/9890000/db79836e39e8/108610.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b45/9890000/db79836e39e8/108610.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b45/9890000/db79836e39e8/108610.fig1.jpg

相似文献

1
Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients.基于达雷妥尤单抗的诱导治疗对瑞典骨髓瘤患者干细胞采集参数的影响。
Haematologica. 2023 Feb 1;108(2):610-614. doi: 10.3324/haematol.2022.281610.
2
Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma.在多发性骨髓瘤中，基于达雷妥尤单抗的诱导治疗后，更高剂量的环磷酰胺可实现最佳的干细胞采集。
Haematologica. 2023 Dec 1;108(12):3502-3505. doi: 10.3324/haematol.2023.283452.
3
[Daratumumab for multiple myeloma].达雷妥尤单抗用于治疗多发性骨髓瘤
Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.
4
Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
5
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.达雷妥尤单抗联合卡非佐米、来那度胺和地塞米松治疗新诊断多发性骨髓瘤患者。
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):701-710. doi: 10.1016/j.clml.2021.05.017. Epub 2021 Jun 9.
6
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.达雷妥尤单抗、泊马度胺和地塞米松联合疗法治疗对达雷妥尤单抗和/或泊马度胺难治的多发性骨髓瘤
Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11.
7
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.在多发性骨髓瘤患者诱导治疗后微小残留病中使用达雷妥尤单抗的短期疗程。
Leuk Lymphoma. 2022 Dec;63(14):3488-3492. doi: 10.1080/10428194.2022.2131417. Epub 2022 Oct 25.
8
Daratumumab for the Treatment of Multiple Myeloma.达雷妥尤单抗治疗多发性骨髓瘤。
Front Immunol. 2018 Jun 4;9:1228. doi: 10.3389/fimmu.2018.01228. eCollection 2018.
9
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.在复发或难治性多发性骨髓瘤患者中，用卡非佐米治疗前后使用达雷妥尤单抗的治疗结果。
Hematol Oncol. 2021 Oct;39(4):521-528. doi: 10.1002/hon.2906. Epub 2021 Aug 2.
10
Daratumumab for the treatment of multiple myeloma.达雷妥尤单抗用于治疗多发性骨髓瘤。
Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2.

引用本文的文献

1
Optimal infused CD34 cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.多发性骨髓瘤患者行 upfront 自体造血干细胞移植时的最优输注 CD34 细胞剂量。
Blood Cancer J. 2024 Oct 31;14(1):189. doi: 10.1038/s41408-024-01165-w.
2
Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study.基于达雷妥尤单抗的治疗方法及在多发性骨髓瘤和其他浆细胞异常增殖症中的临床结果：一项全国性真实世界图表回顾研究的见解
Clin Hematol Int. 2024 Oct 11;6(4):53-66. doi: 10.46989/001c.124362. eCollection 2024.
3

本文引用的文献

1
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.在3期CASSIOPEIA研究中，接受达雷妥尤单抗+硼替佐米/沙利度胺/地塞米松治疗的符合移植条件的新诊断多发性骨髓瘤患者的干细胞产量及移植情况
Haematologica. 2021 Aug 1;106(8):2257-2260. doi: 10.3324/haematol.2020.261842.
2
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor.
达雷妥尤单抗对接受粒细胞集落刺激因子（G-CSF）加按需使用普乐沙福进行造血干细胞动员的多发性骨髓瘤患者采集和植入的影响
Bone Marrow Transplant. 2025 Jan;60(1):79-82. doi: 10.1038/s41409-024-02432-x. Epub 2024 Oct 4.
4
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.抗CD38单克隆抗体疗法对多发性骨髓瘤患者CD34+造血干细胞动员、采集及植入的影响——一项系统评价
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944.
5
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.在标准硼替佐米-沙利度胺-地塞米松方案中加入达雷妥尤单抗对造血干细胞动员与采集、移植后植入及感染并发症的影响：一项病例对照多中心真实世界分析
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024049. doi: 10.4084/MJHID.2024.049. eCollection 2024.
6
Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.新型疗法时代多发性骨髓瘤患者外周血造血干细胞动员的预测因素：单中心经验。
Cancer Med. 2024 Jun;13(11):e7356. doi: 10.1002/cam4.7356.
7
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.达雷妥尤单抗用于骨髓瘤诱导治疗时与干细胞动员受损及移植后血液学恢复延长相关。
Cancers (Basel). 2024 May 13;16(10):1854. doi: 10.3390/cancers16101854.
8
Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges.成人自体/异体移植中的干细胞采集和动员：关键点和未来挑战。
Cells. 2024 Mar 28;13(7):586. doi: 10.3390/cells13070586.
9
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.抗 CD38 单克隆抗体可损害多发性骨髓瘤患者 CD34+细胞的动员，并影响其集落形成能力。
Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.
10
Daratumumab-based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia.基于达雷妥尤单抗的诱导治疗及自体移植用于伴发的多发性骨髓瘤和慢性髓性白血病
EJHaem. 2023 Sep 11;4(4):1152-1156. doi: 10.1002/jha2.765. eCollection 2023 Nov.
3
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
4
Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.预先给予普乐沙福治疗对多发性骨髓瘤患者干细胞动员的临床和成本结果。
Leuk Res. 2019 Oct;85:106215. doi: 10.1016/j.leukres.2019.106215. Epub 2019 Aug 9.
5
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
6
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.来那度胺、硼替佐米与地塞米松联合移植治疗骨髓瘤
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
7
Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.自体干细胞动员时使用普乐沙福抢救后的患者结局：单中心回顾性分析
Transfusion. 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883. Epub 2016 Nov 18.
8
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
9
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.多发性骨髓瘤和淋巴瘤患者的自体造血干细胞动员：欧洲血液与骨髓移植组的立场声明
Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31.
10
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.优化自体干细胞动员策略以改善患者结局：共识指南和建议。
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.